Ukunciphisa i-Itch ye-Eczema yinjongo enkulu yokuNakekela
I-steroids ye-topical iyanceda ekwenzeni unyango lweentlobo ezininzi zezifo zesikhumba kunye ne- pruritus , okuquka i-atopic dermatitis (ebizwa ngokuba yi- eczema ). Njengemithi echasayo, i-steroids ye-headical iyancipha, ikhupha, ikhupha xa isetyenziswe kwesikhumba enye okanye ngaphezulu kweentsuku.
Ngokuqhelekileyo, ugqirha uya kuncoma i-steroid ye-topical ukuze uphathe umntwana (okanye umntu omdala) eczema engakwazi ukulawulwa ngesikhumba se-moisturizers yedwa.
Ziziphi iintlobo ze-Topical Steroids ezikhoyo?
Kukho inani leentlobo ze-steroid ezikhoyo ezifumaneka ngogqirha, kunye ne-hydrocortisone acetate 1% yekremu, ekhoyo kwi-counter ngaphandle komyalelo.
I-steroids yezihloko zifumaneka kwiindidi ezahlukeneyo zamachiza, amandla kunye nezithuthi. Amanye amayeza anamandla (anamandla anikwe umlinganiselo ofanayo wamachiza), kwiindawo eziphezulu, okanye afakwa kwi "imoto" eyahlukeneyo (njengama-creams, i-lotions, i-ointments, njl.), Enokuchaphazela indlela enamandla ngayo i-steroid ye-topic .
Uluphi Uhluko phakathi kweLtion, iCream kunye neAintment Topical Steroid?
Isithuthi se-sticid steroid sichaphazela amandla emachiza. Ukunikezelwa kwe-steroid efanayo ye-headical, uluhlu olulandelayo lumelela amandla amachiza, ukusuka phezulu ukuya ngaphantsi:
- Mafutha
- Creams
- Amanqaku
- ZiSombululo
- Iigel
- Sprays
Ziziphi iindidi ze-Topical Steroids ezisetyenziselwa abantwana?
Ngenxa yokuba abantwana banamathele kwimiphumo emibi ye-static steroids, i-potency ephantsi ye-static steroids kufuneka isetyenziswe xa kunokwenzeka.
Uphando lubonisa ukuba ezimbini ze-topical steroids, i-Cutivate (i-fluticasone propionate) kunye ne-Elocon (i-mometasone furoate), inokuthi ikhuselekile kwiintsana ukususela ngaphantsi kweyeza kunikwa umzimba. Zingasetyenziswa kwakhona kanye ngokuchasene kabini ngosuku. Ukongeza, i-Cutivate iyona kuphela i-steroid i-FDA-evunyelwe abantwana kubantwana abaneminyaka engama-3 ubudala.
Ndiyakwazi ukusebenzisa i-Topical Steroids ebusweni bam?
Ulusu ebusweni lubangelwa yimiphumo emibi ye-static steroid, kwaye ukufumana le mayeza kumaso kunokubangela i-glaucoma okanye i-cataract form formation. Ngoko ke, kuphela ukusetyenziswa kwe-steroids ephantsi kwe-potential kufuneka isetyenziswe ebusweni, kunye nenani elincinci lemithi esetyenziselwa ixesha elifutshane kunokwenzeka.
Ngaba iindawo eziMzimba wam apho ndingayisebenzisi i-Topical Steroids?
Ezinye iindawo zomzimba ziyakhathalela ngokukhethekileyo kwimiphumo ye-steroids ye-topical. Ngokomzekelo, ezinye iinxalenye zomzimba ezinomzimba onqabileyo, njengobuso, iinkophe, kunye nezitho zangasese, zithinteka kakhulu, kwaye kuphela okufunekayo kusetyenziswe kule ndawo. Imimandla yesikhumba sebala, ezifana ne-armpits, groin, nangaphantsi kwamabele, ufumene i-steroid ephezulu ye-topical, i-potency ephantsi ye-steroids kufuneka isetyenziswe ngokuqapha kule mimandla.
Ziziphi iimpembelelo ezingasetyenziswayo ze-Topical Steroids?
Imiphumo emibi evela kwi-steroids yama-topical idlalwa rhoqo kwiindawo zesikhumba apho kusetyenziswa iyeza.
Iziphumo zamacandelo zasekhaya ziquka:
- Ukucocwa kwesikhumba
- Utshintsho lweentlanzi (ukhanyisa okanye ulusu lomnyama)
- I-Telangiectasia (isitya segazi)
- I-Rosacea, i-perioral dermatitis, kunye ne-acne
- Ukwenyuka okuphezulu kwintsholongwane yolusu
- Ukuphulukiswa kwamandla okuphilisa
- Ukuthukuthela, ubomvu, ukutshisa, ukubetha, kunye nokukhangela kwesikhumba
- Ukudibanisa i-dermatitis ngenxa ye-static steroid ngokwayo
Xa i-steroids ye-headical isetyenziselwa kwiindawo ezinkulu zomzimba, indawo zokunyuswa komzimba (umzekelo, ubuso okanye izitho zangasese), okanye ixesha elide elide, umzimba wonke unokuchaphazeleka. Oku kubizwa ngokuba yimpembelelo yenkqubo, kwaye ngelixa lingaqabile, lingabandakanya nayiphi na okanye zonke iimpawu ze- Cushing's syndrome .
Ezinye izinto ezenza ukuba iziphumo zomzimba ze-staticosteroid ezichaphazelekayo zomzimba zibandakanya ubungakanani be-corticosteroid, kunye nokuba ukugqoka i-occlusion kusetyenziswa kwi-steroid.
Ziziphi ezinye zeMifanekiso ze-Topical Steroids ezikhethiweyo ngePowerment?
I-steroids yezihloko zihlala zihlukaniswe ngamaqela angama-7 ngokusekelwe kumgangatho we-potency, kunye neqela 1 liqine kakhulu kwaye iqela lesi-7 liyabuthathaka. Ezi zilandelayo ziyimimiselo ye-steroids esetyenziswa rhoqo kwiqela ngalinye:
- Iqela 1: Temovate (clobetasol) 0.05% ukhilimu kunye neoli, i-Diprolene (betamethasone) 0.05% ukhilimu kunye neoli
- Iqela 2: i-lidex (i-fluocinonide) i-0.05% kuzo zonke iifom, i-Topicort (desoximetasone) 0.25% ukhilimu, i-gel, i-ointment, i-Elocon (i-mometasone furoate) 0.1%
- Iqela 3: I-Topicort (desoximetasone) 0.05% ukhilimu, I-Cutivate (i-fluticasone enexabiso) 0.005%
- Iqela le-4: iWestcort (i-hydrocortisone valerate) i-0.2% i-ointment, i-Kenalog (i-triamcinolone) 0.1% i-cream, i-Elocon (i-mometasone furoate) 0.1% i-cream
- Iqela le-5: Chukumisa (i-fluticasone efanelekileyo) 0.05% ukhilimu, i-Westcort (i-hydrocortisone valerate) 0.2% i-cream
- Iqela le-6: Ukuxhathisa (deonide) 0.05% ukhilimu
- Iqela le-7: I-Cortaid (i- hydrocortisone acetate ) zonke iifom kunye namaqondo
Ngaba i-Hydrocortisone I-Cream Work Work Enough, okanye Ngaba Ndiyifuna Imithi?
Kuxhomekeke kubukhulu belikhumba. Ukufumana i- dermatitis ye-atopic elula, umzekelo, i-cream-hydro-coronisone e-low-counter-pot anti-pottery iyakuthi isebenze kakuhle. Ukuba i-eczema inzima, inokuma, okanye iquka isikhumba esinqabileyo (njengeentendelezo okanye iisityambo), isicatshulwa esisigxina se-steroid sisenokufuneka.
ILizwi
Enye into ebalulekileyo kukuba akufanele usebenzise enye imithi yomnxeba we-static steroid, njengoko ungazi ukuba yintoni na loo mayeza ayenzelwe ekuqaleni. I-sticidic steroid ingaba yindlela enamandla, kwaye awufuni ukusebenzisa loo mayeza kumalungu athile omzimba, afana nobuso okanye kwi-fold folds.
> Imithombo:
> Chen TM, Aeling JL.Topical Steroids. Ku: Fitzpatrick JE, Morelli JG, eds. Iimfihlakalo zeDermatology. Wesithathu. Philadelphia: Mosby; 2007: 408-16.
> Schneider L et al. I-aicic dermatitis: uhlaziyo lwe-parameter update 2012. J Allergy Clin Immunol. 2013 Feb; 131 (2): 295-9.e1-27.